

**REMARKS/ARGUMENTS**

This Substitute Amendment is being filing in order to correct the inadvertent omission of underlining to show the addition to claim 16 set forth in pages 4 and 5 of the Amendment. Otherwise it is identical to the version/Amendment submitted by facsimile on August 4, 2005.

Applicants hereby affirm their election of claims 7-8 and 16. as discussed in pages 2 and 3 of the Action. Furthermore Applicants reserve the right to file a divisional application to the now cancelled, non-elected claims during the pendency of the present application.

**Claim Rejection – 35 USC §112**

Claim 16 has been rejected under 35 U.S.C. §112, first paragraph, as being indefinite. Claim 16 has been amended in accordance with Examiner's helpful suggestions on page 4 of the Action, thereby obviating that rejection.

**Objection to Abstract**

The abstract has been amended to obviate the objection in accordance with suggestions in page 4 of the Action.


Response dated August 9, 2005

Reply to Office action mailed May 6, 2005

### Conclusions

Applicants respectfully request further examination of this application, and a favorable decision thereon. A prompt Notice of Allowance is respectfully solicited. If the examination of this application can be expedited by a telephone conversation, the Examiner is invited to call the undersigned practitioner, collect if necessary.

Respectfully submitted,



Irving Newman, Reg. No. 22,638  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-2785  
Telefax (908) 231-2626  
Aventis Docket No. 2541US CNT